Prognostic factors relating to esophageal cancer

Minerva Chirurgica

Volumn 57, Issue 6, 2002, Pages 789-794

  Butsch, J ^a   Christein, J D ^a   Millikan, K ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Drug therapy; Esophageal neoplasms, diagnosis; Esophageal neoplasms, therapy; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CELL ADHESION MOLECULE; CYCLIN D1; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P16; PROTEIN P21; PROTEIN P53; TUMOR MARKER; UVOMORULIN;

ADENOCARCINOMA; ALLELIC EXCLUSION; ANEUPLOIDY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CERVICAL LYMPH NODE; EARLY DIAGNOSIS; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; HISTOPATHOLOGY; HOSPITAL; HUMAN; LARYNGEAL NERVE; LARYNX TUMOR; LYMPH NODE; LYMPHADENECTOMY; METASTASIS; MORBIDITY; ONCOGENE C ERB; PROGNOSIS; REVIEW; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; TUMOR BIOPSY; TUMOR LOCALIZATION;

ADENOCARCINOMA; ESOPHAGEAL NEOPLASMS; HUMANS; PROGNOSIS;

EID: 0036931932     PISSN: 00264733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Wang HH, Antonioli DA, Goldman H. Comparative features of esophageal and gastric adenocarcinomas: recent changes in type and frequency. Hum Pathol 1986;17:482-7.
2. Bolton JS, Ochsner JL, Abdoh AA. Surgical management of esophageal cancer a decade of change. Ann Surg 1994;51:475-80.
3. Roder JD, Stein HJ, Siewert JR. Prognostic markers in patients with carcinoma of the oesophagus. Eur J Gastroenterol Hepatol 1994;6:663-9.
4. Holscher AH, Bollschweiler E, Bumm R, Barrels H, Hofler H, Siewert JR. Prognostic factors of resected adenocarcinoma of the esophagus. Surgery 1995;118:845-55.
5. Collard JM, Otte JB, Fiasse R, Laterre PF, De Kock M, Longueville J et al. Skeletonizing en bloc esophagectomy for cancer. Ann Surg 2001;234:25-32.
6. Akiyama H, Tsurumaru M, Kawamura T, Ono Y. Principles of surgical treatment for carcinoma of the esophagus: analysis of lymph node involvement. Ann Surg 1981;194:438-46.
7. Tachibana M. Esophageal cancer with distant lymph node metastasis: prognostic significance of metastatic lymph node ratio. J Clin Gastroenterol 2000;31:318-22.
8. Skinner DB, Little AG, Ferguson MK, Soriano A, Staszak VM. Selection of operation for esophageal cancer based on staging. Ann Surg 1986;204:391-401.
9. Akiyama H, Tsurumaru M, Udagawa H, Kajiyawa Y. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 1994;220:364-72.
10. Altorki N, Skinner D. Should en bloc esophagectomy be the standard of care for esophageal carcinoma? Ann Surg 2001;234:581-7.
11. Hosch SB, Stoecklein NH, Pichlmeier U, Rehders A, Scheunemann P, Niendorf A et al. Esophageal cancer: the mode of lymphatic tumor cell spread and its prognostic significance. J Clin Oncol 2001;19:1970-5.
12. Tabira Y, Okuma T, Kondo K, Kitamura N. Indications for 3-field dissection followed by esophagectomy for advanced carcinoma of the thoracic esophagus. J Thorac Cardiovasc Surg 1999;117:239-45.
13. Baba M, Aikou T, Yoshinaka H, Natsugoe S, Fukumoto T, Shimazu H et al. Long-term results of subtotal esophagectomy with 3-field lymphadenectomy for carcinoma of the thoracic esophagus. Ann Surg 1994;219:310-6.
14. rd ed. Philadelphia: JB Lippincott; 1988. p.63-7.
15. Eloubeidi MA, Wallace MB, Hoffman BJ, Leveen MB, Van Velse A, Hawes RH et al. Predictors of survival for esophageal cancer patients with and without celiac axis lymphadenopathy: impact of staging endosonography. Ann Thorac Surg 2001;72:212-20.
16. Akiyama H, Tsurumaru M, Kawamura T, Ono Y. Principles of surgical treatment for carcinoma of the esophagus: analysis of lymph node involvement. Ann Surg 1981;194:438-46.
17. Kato H, Igaki H, Tachimori Y, Watanabe H, Tsubosa Y, Nakanishi Y. Assessment of cervical lymph node metastasis in the staging of thoracic esophageal carcinoma. J Surg Oncol 2000;74:282-5.
18. Roder JD, Busch R, Stein HJ, Fink U, Siewert JR. Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus. Br J Surg 1994;81:410-3.
19. Hagen JA, Peters JH, DeMeester TR. Superiority of extended en bloc esophagogastrectomy for carcinoma of the lower esophagus and cardia. J Thorac Cardiovasc Surg 1993;106:850-9.
20. Siewert JR, Stein HJ. Lymphadenectomy for esophageal cancer. Langenbecks Arch Surg 1999;384:141-8.
21. Stein HJ, Sendler A, Fink U, Siewert JR. Multidisciplinary approach to esophageal and gastric cancer. Surg Clin North Am 2000;80:659-86.
22. Nigro JJ, De Meester SR, Hagen JA, De Meester TR, Peters JH, Kijabu M et al. Node status in transmural esophageal adenocarcinoma and outcome after en bloc esophagectomy. J Thorac Cardiovasc Surg 1999;117:960-8.
23. Hölscher AH, Bollschweiler E, Bumm R, Bartels H, Höfler H, Siewert JR. Prognostic factors of resected adenocarcinoma of the esophagus. Surgery 1995;118:845-55.
24. Natsugoe S, Mueller J, Stein HJ, Feith M, Hofler H, Siewert JR. Micrometastasis and tumor cell microinvolvement of lymph nodes from esophageal squamous cell carcinoma: frequency, associated tumor characteristics, and impact on prognosis. Cancer 1998;83:858-66.
25. Komukai S, Nishimaki T, Suzuki T, Kanda T, Kuwabara S, Hatakeyama K. Significance of immunohistochemical nodal micrometastasis as a prognostic indicator in potentially curable oesophageal carcinoma. Br J Surg 2002;89:213-9.
26. Komukai S, Nishimaki T, Watanabe H, Ajioka Y, Suzuki T, Hatakeyama K. Significance of immunohistochemically demonstrated micrometastases to lymph nodes in esophageal cancer with histologically negative nodes. Surgery 2000;127:40-6.
27. Sato F, Shimada Y, Li Z, Watanabe G, Maeda M, Imamura M. Lymph node micrometastasis and prognosis in patients with oesophageal squamous cell carcinoma. Br J Surg 2001;88:426-32.
28. Christein JD, Millikan K. Prognostic factors associated with resectable carcinoma of the esophagus. Am Surg 2002;68:258-62.
29. Stark SP, Romberg MS, Pierce GE, Hermreck AS, Jewell WR, Moran JF et al. Transhiatal versus transthoracic esophagectomy for adenocarcinoma of the distal esophagus and cardia. Am J Surg 1996;172:478-82.
30. Horstmann O, Verreet PR, Becker H, Ohmann C, Roher HD. Transhiatal oesophagectomy compared with transthoracic resection and systematic lymphadenectomy for the treatment of oesophageal cancer. Eur J Surg 1995;161:557-67.
31. Goldminc M, Maddern G, Le Prise E, Meunier B, Campion JP, Launois B. Oesophagectomy by a transhiatal approach or thoracotomy: a prospective randomized trial. Br J Surg 1993;80:367-70.
32. Bolton JS, Sardi A, Bowen JC, Ellis JK. Transhiatal and transthoracic esophagectomy a comparative study. J Surg Oncol 1992;51:249-53.
33. Putnam JB Jr, Suell DM, McMurtrey MJ, Ryan MB, Walsh GL, Natarajan G et al. Comparison of 3 techniques of esophagectomy within a residency training program. Ann Thorac Surg 1994;57:319-25.
34. Gertsch P, Vauthey JN, Lustenberger AA, Friedlander-Klar H. Long-term results of transhiatal esophagectomy for esophageal carcinoma a multivariate analysis of prognostic factors. Cancer 1993;72:2312-9.
35. Hagen JA, De Meester SR, Peters JH, Chandrasoma P, De Meester TR. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg 2001;234:520-30.
36. Lerut TE, de Leyn P, Coosemans W, Van Raemdonck D, Cuypers P, Van Cleynenbreughel B. Advanced esophageal carcinoma. World J Surg 1994;18:379-87.
37. Tabira Y, Yasunaga M, Tanaka M, Nakano K, Sakaguchi T, Nagamoto N et al. Recurrent nerve nodal involvement is associated with cervical nodal metastasis in thoracic esophageal carcinoma. J Am Coll Surg 2000;191:232-7.
38. Siewert JR. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg 2001;234:360-9.
39. Igaki H, Kato H, Tachimori Y, Daiko H, Fukaya M, Yajima S, Nakanishi Y. Clinicopathologic characteristics and survival of patients with clinical Stage I squamous cell carcinomas of the thoracic esophagus treated with 3-field lymph node dissection. Eur J Cardiothorac Surg 2001;20:1089-94.
40. Peracchia A, Bonavina L. Carcinoma del cardias. Rome: Studio Tipografico SP; 1999. p.157-72.
41. Orringer MB, Marshall B, Iannettoni MD. Transhiatal esophagectomy clinical experience and refinements. Ann Surg 1999;230:392-403.
42. Ellis FH Jr. Standard resection for cancer of the esophagus and cardia. Surg Oncol Clin North Am 1999;8:279-94.
43. Lieberman MD, Shriver CD, Bleckner S, Burt M. Carcinoma of the esophagus. Prognostic significance of histologic type. J Thorac Cardiovasc Surg 1995;109:130-9.
44. Karl RC, Schreiber R, Boulware D. Factors affecting morbidity, mortality, and survival in patients undergoing Ivor-Lewis esophagogastrectomy. Ann Surg 2000;231:635-43.
45. Ide H, Equchi R, Nakamura T. Extended lymph node dissection for thoracic esophageal cancer: efficacy of three field dissection based on preoperative staging. Jpn J Gastroenterol Surg 1995;28:951-5.
46. Altorki NK, Girardi L, Skinner DB. En bloc esophagectomy improves survival for stage III esophageal cancer. J Thorac Cardiovasc Surg 1997;114:948-55.
47. Swisher SG, Deford L, Merriman KW, Walsh GL, Smythe R, Vaporicyan A et al. Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer. J Thorac Cardiovasc Surg 2000;119:1126-32.
48. Mathews HR, Powell DJ, McConkey CC. Effect of surgical experience on the results of resection for oesophageal carcinoma. Br J Surg 1986;73:621-3.
49. Miller JD, Jain MK, de Gara CJ, Morgan D, Urschel JD. Effect of surgical experience on results of esophagectomy for esophageal carcinoma. J Surg Oncol 1997;65:20-1.
50. van Lanschot JJ, Hulscher JB, Buskens CJ, Tilanus HW, ten Kate FJ, Obertop H. Hospital volume and hospital mortality for esophagectomy. Cancer 2001;91:1574-8.
51. Dimick JB, Cattaneo SM, Lipsett PA, Pronovost PJ, Heitmiller RF. Hospital volume is related to clinical and economic outcomes of esophageal resection in Maryland. Ann Thorac Surg 2001;72:334-41.
52. Kuo EY, Chang Y, Wright CD. Impact of hospital volume on clinical and economic outcomes for esophagectomy. Ann Thorac Surg 2001;72:1118-24.
53. Skinner DB. En-bloc resection for neoplasms of the esophagus and cardia. J Thorac Cardiovasc Surg 1983;85:59-71.
54. Tachibana M, Tabara H, Kotoh T, Kinugasa S, Dhar DK, Hishikawa Y et al. Prognostic significance of perioperative blood transfusions in resectable thoracic esophageal cancer. Nagasue N Am J Gastroenterol 1999;94:757-65.
55. Craig SR, Adam DJ, Yap PL, Leaver HA, Elton RA, Cameron EW et al. Effect of blood transfusion on survival after esophagogastrectomy for carcinoma. Ann Thorac Surg 1998;66:356-61.
56. Conio M, Gostout CJ. Histopathologic findings predicting lymph node metastasis and prognosis of patients with superficial esophageal carcinoma. Analysis of 240 surgically resected tumors. Gastrointest Endosc 2001; 54:668-9.
57. Mathew R, Arora S, Khanna R, Mathur M, Shukla NK, Ralhan R. Alterations in p53 and pRb pathways and their prognostic significance in oesophageal cancer. Eur J Cancer 2002;38:832-41.
58. Makoto O. Prognostic significance of thymidine phosphorylase and p53 co-expression in esophageal squamous cell carcinoma. Oncol Rep 2002;9:23-8.
59. Natsugoe S, Matsumoto M, Okumura H, Nakashima S, Sakamoto F, Sakita H et al. Bax and Bcl-X(L) expression are not related to prognosis in patients with advanced esophageal squamous cell carcinoma. Cancer Lett 2001;174:91-7.
60. Takayama T. Bcl-X expression in esophageal squamous cell carcinoma: association with tumor progression and prognosis. J Surg Oncol 2001;78:116-23.
61. Matsumoto M. Clinical significance and prognostic value of apoptosis related proteins in superficial esophageal squamous cell carcinoma. Ann Surg Oncol 2001;8:598-604.
62. Sturm I. Analysis of p53/BAX/p16(ink4a/CDKN2) in esophageal squamous cell carcinoma: high BAX and p16(ink4a/CDKN2) identifies patients with good prognosis. J Clin Oncol 2001;19:2272-81.
63. Shiozaki H. A multi-institutional study of immunohistochemical investigation for the roles of cyclin D1 and E-cadherin in superficial squamous cell carcinoma of the esophagus. J Surg Oncol 2002;79:166-73.
64. Ohbu M. Expression of cell cycle regulatory proteins in the multistep process of oesophageal carcinogenesis: stepwise over-expression of cyclin E and p53, reduction of p21(WAF1/CIP1) and dysregulation of cyclin D1 and p27(KIP1). Histopathology 2001;39:589-96.
65. Shimada H. Prognostic significance of serum P53 antibody in patients with esophageal squamous cell carcinoma. Surgery 2002;132:41-7.
66. Bergqvist AS. Serum p53 autoantibodies as prognostic marker in patients with oesophageal carcinoma. Anticancer Res 2001;21:4141-5.
67. Saeki H, Ohno S, Miyazaki M, Araki K, Egashira A, Kawaguchi H et al. p53 protein accumulation in multiple oesophageal squamous cell carcinoma: relationship to risk factors. Oncology 2002;62:1715-9.
68. Ito T, Kaneko K, Makino R, Ito H, Konishi K, Kurahashi T et al. Prognostic value of p53 mutations in patients with locally advanced esophageal carcinoma treated with definitive chemoradiotherapy. J Gastroenterol 2001;36:303-11.
69. Ireland AP, Shibata DK, Chandrasoma P, Lord RV, Peters JH, DeMeester TR. Clinical significance of p53 mutations in adenocarcinoma of the esophagus and cardia. Ann Surg 2000;231:179-87.
70. Altorki N, Kent M, Ferrara C, Port J. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg 2002;236:177-83.